These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 21411496

  • 1. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
    Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ.
    J Pharmacol Exp Ther; 2011 Jun; 337(3):786-96. PubMed ID: 21411496
    [Abstract] [Full Text] [Related]

  • 2. New, potent, selective, and short-acting peptidic V1a receptor agonists.
    Wisniewski K, Galyean R, Tariga H, Alagarsamy S, Croston G, Heitzmann J, Kohan A, Wisniewska H, Laporte R, Rivière PJ, Schteingart CD.
    J Med Chem; 2011 Jul 14; 54(13):4388-98. PubMed ID: 21688787
    [Abstract] [Full Text] [Related]

  • 3. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.
    J Pept Sci; 2006 Mar 14; 12(3):190-8. PubMed ID: 16130178
    [Abstract] [Full Text] [Related]

  • 4. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.
    J Med Chem; 2007 Feb 22; 50(4):835-47. PubMed ID: 17300166
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity.
    Andrés M, Trueba M, Guillon G.
    Br J Pharmacol; 2002 Apr 22; 135(7):1828-36. PubMed ID: 11934825
    [Abstract] [Full Text] [Related]

  • 6. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.
    J Med Chem; 2004 Apr 22; 47(9):2375-88. PubMed ID: 15084136
    [Abstract] [Full Text] [Related]

  • 7. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Apr 22; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1A) receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245).
    Russell R, Doyle R, Turner J, Attkins N, Ramsey S, Weibley L, Bateman L, Bictash M, Neal-Morgan S, Ivarsson M, Pullen N.
    Eur J Pharmacol; 2011 Nov 30; 670(2-3):347-55. PubMed ID: 21958878
    [Abstract] [Full Text] [Related]

  • 9. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
    Nakamura S, Yamamura Y, Itoh S, Hirano T, Tsujimae K, Aoyama M, Kondo K, Ogawa H, Shinohara T, Kan K, Tanada Y, Teramoto S, Sumida T, Nakayama S, Sekiguchi K, Kambe T, Tsujimoto G, Mori T, Tominaga M.
    Br J Pharmacol; 2000 Apr 30; 129(8):1700-6. PubMed ID: 10780976
    [Abstract] [Full Text] [Related]

  • 10. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
    Tsukamoto I, Koshio H, Akamatsu S, Kuramochi T, Saitoh C, Yatsu T, Yanai-Inamura H, Kitada C, Yamamoto E, Sakamoto S, Tsukamoto S.
    Bioorg Med Chem; 2008 Nov 01; 16(21):9524-35. PubMed ID: 18835174
    [Abstract] [Full Text] [Related]

  • 11. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M, Cheng LL, Stoev S, Bankowski K, Przybyiski J, Klis WA, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1995 Nov 01; 1(1):66-79. PubMed ID: 9222985
    [Abstract] [Full Text] [Related]

  • 12. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
    Tahara A, Tsukada J, Tomura Y, Kusayama T, Wada K, Ishii N, Taniguchi N, Suzuki T, Yatsu T, Uchida W, Shibasaki M.
    Pharmacol Res; 2005 Mar 01; 51(3):275-81. PubMed ID: 15661579
    [Abstract] [Full Text] [Related]

  • 13. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
    Heinemann A, Horina G, Stauber RE, Pertl C, Holzer P, Peskar BA.
    Br J Pharmacol; 1998 Nov 01; 125(6):1120-7. PubMed ID: 9863637
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.
    Pena A, Murat B, Trueba M, Ventura MA, Bertrand G, Cheng LL, Stoev S, Szeto HH, Wo N, Brossard G, Serradeil-Le Gal C, Manning M, Guillon G.
    Endocrinology; 2007 Sep 01; 148(9):4136-46. PubMed ID: 17495006
    [Abstract] [Full Text] [Related]

  • 15. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S, Cheng LL, Olma A, Klis WA, Manning M, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1999 Mar 01; 5(3):141-53. PubMed ID: 10323558
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
    Gunnet JW, Wines P, Xiang M, Rybczynski P, Andrade-Gordon P, de Garavilla L, Parry TJ, Cheung WM, Minor L, Demarest KT, Maryanoff BE, Damiano BP.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):333-42. PubMed ID: 18599033
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
    Tsukamoto I, Koshio H, Kuramochi T, Saitoh C, Yanai-Inamura H, Kitada-Nozawa C, Yamamoto E, Yatsu T, Shimada Y, Sakamoto S, Tsukamoto S.
    Bioorg Med Chem; 2009 Apr 15; 17(8):3130-41. PubMed ID: 19321349
    [Abstract] [Full Text] [Related]

  • 18. Vasopressin in sepsis and septic shock.
    Kampmeier TG, Rehberg S, Westphal M, Lange M.
    Minerva Anestesiol; 2010 Oct 15; 76(10):844-50. PubMed ID: 20935620
    [Abstract] [Full Text] [Related]

  • 19. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
    Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.
    Br J Pharmacol; 2001 Jul 15; 133(5):746-54. PubMed ID: 11429400
    [Abstract] [Full Text] [Related]

  • 20. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
    Derick S, Cheng LL, Voirol MJ, Stoev S, Giacomini M, Wo NC, Szeto HH, Ben Mimoun M, Andres M, Gaillard RC, Guillon G, Manning M.
    Endocrinology; 2002 Dec 15; 143(12):4655-64. PubMed ID: 12446593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.